P
PolyNovo
Synthetic biodegradable matrix for complex wound reconstruction.
About PolyNovo
PolyNovo Limited is a medical technology company that designs, develops, and manufactures dermal regeneration solutions. The company was established in 2004 as a spin-off from Australia's Commonwealth Scientific and Industrial Research Organisation (CSIRO) by researchers Thilak Gunatillake, Raju Adhikari, and Roshan Mayadunne, who developed a novel biodegradable polyurethane. The technology's potential for wound care was explored in collaboration with burns surgeon Professor John Greenwood, inspired by the need for better treatments following events like the 2002 Bali bombings. After a period of restructuring, the company relisted in 2014 as PolyNovo and has since focused purely on commercializing its medical device platform. The company's core business revolves around its proprietary NovoSorb® technology, a patented family of biocompatible and bioresorbable polymers. This technology is the foundation for its flagship product, NovoSorb® BTM (Biodegradable Temporizing Matrix). NovoSorb BTM is a fully synthetic, bilayer medical device designed for the treatment of complex wounds, such as severe burns and trauma, where the dermal layer of skin has been lost. The device consists of a 2mm biodegradable open-cell foam that acts as a scaffold for the body to regenerate a new dermal layer, and a temporary sealing membrane that protects the wound and prevents moisture loss. Once the new tissue is vascularized, the seal is removed, ready for definitive closure. A key differentiator from biologic-based competitors is that its synthetic nature does not provide a food source for bacteria, making it robust in the presence of infection. PolyNovo's business model is focused on the sale of its NovoSorb products directly to hospitals and surgeons. The company has established a significant direct sales force, particularly in the United States, which is its largest market and accounts for the majority of its revenue. The firm also operates in Australia, New Zealand, the UK, and Ireland, and uses distributors to access markets in Europe and Canada. Revenue is primarily generated from sales of NovoSorb BTM and its newer product, NovoSorb MTX, a single-layer version for wounds that do not require a sealing membrane. The company is pursuing growth by expanding the indications for its existing products, deepening penetration in current markets, and entering new geographic territories like China and Japan. It is also developing new products based on the NovoSorb platform for applications in hernia repair and breast reconstruction.
Source: Dealroom company dataNews
Open roles
PolyNovo in the Melbourne ecosystem
The PolyNovo office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
HHS Administration for Strategic Preparedness and Response- IFIndustry R&D Infrastructure Fund
Series B and later1 investor entered at this stage
- MUMonash University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Patents
7 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about PolyNovo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PolyNovo on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

